An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
View ORCID ProfileJosue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
doi: https://doi.org/10.1101/2022.02.26.22271364
Josue Antonio Estrada
1Medigen Vaccine Biologics, Taipei, Taiwan
Chien-Yu Cheng
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
3Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University
Shin-Yen Ku
4Department of Nursing, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Hui-Chun Hu
4Department of Nursing, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Hsiu-Wen Yeh
4Department of Nursing, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Yi-Chun Lin
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Cheng-Pin Chen
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
5School of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan
Shu-Hsing Cheng
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
6School of Public Health, Taipei Medical University, Taipei, Taiwan
I-Feng Lin
3Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University
Article usage
Posted March 01, 2022.
An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
Josue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
medRxiv 2022.02.26.22271364; doi: https://doi.org/10.1101/2022.02.26.22271364
An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
Josue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
medRxiv 2022.02.26.22271364; doi: https://doi.org/10.1101/2022.02.26.22271364
Subject Area
Subject Areas
- Addiction Medicine (365)
- Allergy and Immunology (685)
- Anesthesia (184)
- Cardiovascular Medicine (2727)
- Dermatology (234)
- Emergency Medicine (411)
- Epidemiology (12378)
- Forensic Medicine (10)
- Gastroenterology (783)
- Genetic and Genomic Medicine (4236)
- Geriatric Medicine (394)
- Health Economics (698)
- Health Informatics (2736)
- Health Policy (1015)
- Hematology (369)
- HIV/AIDS (874)
- Medical Education (404)
- Medical Ethics (111)
- Nephrology (450)
- Neurology (4014)
- Nursing (216)
- Nutrition (594)
- Oncology (2114)
- Ophthalmology (603)
- Orthopedics (251)
- Otolaryngology (310)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (475)
- Pediatrics (1145)
- Primary Care Research (465)
- Public and Global Health (6632)
- Radiology and Imaging (1441)
- Respiratory Medicine (883)
- Rheumatology (418)
- Sports Medicine (350)
- Surgery (462)
- Toxicology (57)
- Transplantation (192)
- Urology (171)